Biomatter raises $18m Series A for custom enzyme design
Astanor leads an oversubscribed round to expand Biomatter’s enzyme platform, US commercial team and Vilnius laboratory capacity.
Biomatter has closed an $18 million Series A led by Astanor, with existing investors UVC Partners, Inventure and Metaplanet participating. The Vilnius company designs custom enzymes for specific chemical reactions and industrial uses.
Designing around the reaction
Biomatter combines computational models with laboratory testing to create enzymes suited to customer requirements. Its work serves applications in pharmaceuticals, diagnostics, agriculture and industrial biotechnology.
Expanding design and testing capacity
The funding will support a 2,000-square-metre enzyme design and testing facility in Vilnius, scheduled to open in 2027. Biomatter also plans to expand its US commercial team and continue developing its computational platform and enzyme dataset.
Use of funds
Open a 2,000-square-metre enzyme design and testing facility in Vilnius in 2027.
Expand the US commercial team and develop the computational platform and enzyme dataset.